Literature DB >> 2909757

Reversal of 5-fluorouracil-induced myelosuppression by prolonged administration of high-dose uridine.

C J van Groeningen1, G J Peters, A Leyva, E Laurensse, H M Pinedo.   

Abstract

The effect of high-dose uridine on 5-fluorouracil (5-FU)-induced toxicity was investigated. Nine patients were treated weekly with 5-FU at increasing dosages. Five patients developed dose-limiting leukopenia, and four patients developed thrombocytopenia. At dose-limiting toxicity, 5-FU treatment was repeated and followed after 3 hours by intermittent iv infusion of uridine (2 g/m2 per hr) during 72 hours. Leukopenia was reversed for several weeks but thrombocytopenia was not. Side effects consisted of mild rises in body temperature. The pharmacokinetics of uridine were similar to those observed with single-agent uridine. Our data indicate that high-dose uridine can reduce the severity of 5-FU-induced myelosuppression.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2909757     DOI: 10.1093/jnci/81.2.157

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  7 in total

1.  Improved Antitumor Activity of the Fluoropyrimidine Polymer CF10 in Preclinical Colorectal Cancer Models through Distinct Mechanistic and Pharmacologic Properties.

Authors:  William H Gmeiner; Anthony Dominijanni; Alex O Haber; Lais P Ghiraldeli; David L Caudell; Ralph D'Agostino; Boris C Pasche; Thomas L Smith; Zhiyong Deng; Sezgin Kiren; Chinnadurai Mani; Komaraiah Palle; Jonathan R Brody
Journal:  Mol Cancer Ther       Date:  2020-12-23       Impact factor: 6.261

2.  Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study.

Authors:  James H Doroshow; Sheryl McCoy; John S Macdonald; Brian F Issell; Taral Patel; Patrick W Cobb; Kathleen J Yost; James L Abbruzzese
Journal:  Invest New Drugs       Date:  2006-11       Impact factor: 3.850

3.  Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on the pharmacokinetics of uridine in rhesus monkeys: implications for chemotherapy.

Authors:  J P Sommadossi; E M Cretton; L B Kidd; H M McClure; D C Anderson; M H el Kouni
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Biochemical consequences of 5-fluorouracil gastrointestinal toxicity in rats; effect of high-dose uridine.

Authors:  J Kralovanszky; N Prajda; S Kerpel-Fronius; T Bagrij; E Kiss; G J Peters
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

5.  Schedule-dependency of in vivo modulation of 5-fluorouracil by leucovorin and uridine in murine colon carcinoma.

Authors:  J C Nadal; C J van Groeningen; H M Pinedo; G J Peters
Journal:  Invest New Drugs       Date:  1989-07       Impact factor: 3.850

6.  A narrative review of genetic factors affecting fluoropyrimidine toxicity.

Authors:  William H Gmeiner
Journal:  Precis Cancer Med       Date:  2021-12-30

7.  Uridine phosphorylase 1 associates to biological and clinical significance in thyroid carcinoma cell lines.

Authors:  Yaoyao Guan; Adheesh Bhandari; Xiaohua Zhang; Ouchen Wang
Journal:  J Cell Mol Med       Date:  2019-09-09       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.